MoonLake Immunotherapeutics
MoonLake’s IL-17 Drug Gains Momentum with New Phase 2 Success
Anika Sharma
MoonLake Immunotherapeutics has achieved promising results in a phase 2 trial for its IL-17 inhibitor, sonelokimab, aimed at treating inflammatory ...
